AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision ...

An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...

A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates. The results from the trial showed that the ...

Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation ...

The market for radiopharmaceuticals has the potential to grow to "tens of billions" if the drugs are proven to be effective. AstraZeneca's bladder cancer drug durvalumab, called Imfinzi, reduced the ...

AstraZeneca's lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...

AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the ...

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...

Also Read: AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities. Dato-DXd is an engineered TROP2-directed DXd antibody-drug conjugate ... on Lung Cancer (WCLC), the ...